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Abstract
Addictive diseases such as those stemming from the use of alcohol, cocaine and opioids
lead to serious negative consequences at both the individual and societal level. Over the last two
decades, there has been a significant increase in opioid prescriptions and addiction. The
potential for addiction is related to factors that include genetics, prescriber behavior, user
behavior and characteristics, in addition to environmental and systemic determinants. One
measure of the seriousness of the opioid epidemic is the number of overdose deaths. In 2017,
drug overdoses killed over seventy thousand Americans, and overdose deaths are projected to
increase in the future. Despite the risk of addiction and overdose, opioids are commonly
prescribed to combat pain. This paper uses cross-sectional county and state level data to
examine the socioeconomic, demographic, and community level factors that are important in
explaining opioid overdose deaths

I.

Introduction: Addiction, Opioids, and the Opioid Epidemic

Understanding the opioid epidemic and developing effective policy solutions in addition to
treatment options for opioid addiction requires an interdisciplinary approach. The range of
relevant literature incorporates the biological/chemical and non-biological causes of addiction,
pain prevalence and its management, the historical events leading to the role of opioids in
treating pain, and knowledge about the epidemic from empirical studies.
A.

Addiction and Opioids
1. Addictive Diseases Are Costly

Addictive diseases such as those stemming from the use of alcohol, cocaine and opioids
lead to serious negative consequences at both the individual and societal level. Addiction
adversely affects an individual’s mental and physical health. In addition, the societal and
economic costs are substantial. These diseases have been associated with an increase in other
diseases such as hepatitis, domestic and child abuse, crime, and lost wages and employment.
2. Addiction is a Chronic Brain Disease
Addiction is a chronic disease of the brain that is characterized by compulsive substance
use, impaired control, craving, and social problems. Like other chronic diseases, addiction often
involves cycles of relapse and remission. (Dennis et al 2007, Sussman and Sussman 2011). The
human brain consists of billions of complex cells called neurons which are organized into
networks. When a neuron receives enough signals from other neurons, it sends its own signal to
the other neurons in its network. Some drugs interfere with this process of communication by
mimicking the signals of natural neurons (NIDA 2018). This inference can lead to changes in
the structure of the brain and addiction.
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The purpose of prescription opioids is to effectively manage pain; however, patients
using opioids risk becoming addicted to the medication. Just under a third of opioid
prescriptions are estimated to be misused (Doyle 2016). Opioid addiction is characterized by
dependence on opioid substances. The brain is naturally inclined to repeat actions that stimulate
the reward system or provoke feelings of pleasure. Once a person has taken opiates, their brain
wants to repeat the pleasurable feeling and effectively trains itself to be addicted to drugs. On a
neurological level, opioids attach to a neuron’s opioid receptor in the brain and block pain
(Labonville 2017, Van Zee 2009). Even though opioid addiction is treatable like many other
chronic diseases, in practice, it is often untreated and stigmatized (Chandler et al 2009, Dennis et
al 2007). Because drug abuse changes the structure of the brain, opioid addiction is progressive
if left untreated, resulting in a significant impact on mental and physical health (Weber 2019).
3. Factors Affecting Addiction
In 2011, The American Society of Addictions Medicine (ASAM) released a new
definition of addiction which focuses on addiction as a chronic brain disorder rather than a
behavioral problem. Their definition states:
Addiction is a treatable, chronic medical disease involving complex interactions among brain
circuits, genetics, the environment, and an individual’s life experiences. People with addiction
use substances or engage in behaviors that become compulsive and often continue despite
harmful consequences. (ASAM 2011)
It has been suggested that genetics account for about 50% of the likelihood that
someone will develop an addiction. There are many other factors that determine an individual’s
likelihood of addiction, however, having a family history of addiction significantly increases the
risk of addiction. Environmental factors such as family interactions and culture interact with an
individual’s biological factors and affect the extent to which genetic factors exert their influence
(Smith 2012). In addition, the potential for addiction is related to factors that include individual
2

and psychological characteristics, socioeconomic status, and geographical area. Public policy
also plays an important role. For example, government regulation determines both the viability
of opioid prescriptions and accessibility of opioid addiction treatment.
4. Types of Opioids
The term “opioid” typically includes opiates, semi-synthetic opioids and synthetic
opioids. Opiates are natural substances that originate from opium that is extracted from the
opium poppy. Opium poppies contain more than twenty different opiates (Labonville 2017).
Of those opiates, only four are used by the medical industry: morphine, codeine, thebaine and
papaverine. Morphine and codeine are two of the oldest pain medications still prescribed by
doctors today (Elkins 2018).
Although semi-synthetic and synthetic opioids bind to the same receptors in the brain as
opiates, they do not occur naturally. While synthetic opioids are entirely manufactured, semisynthetic opioids are a hybrid resulting from chemical modifications to opiates (Labonville
2017). For example, thebaine is converted into other chemicals, such as oxycodone or
hydrocodone. Therefore, oxycodone and hydrocodone are classified as semi-synthetic opioids.
They are popular pain medications. Well-known synthetic opioids include methadone, fentanyl,
and meperidine (Elkins 2018).
Opioids are also categorized as a narcotic. According to the Drug Enforcement
Administration, the term “narcotic” was once used to describe any drug that relieved pain and
caused relaxation, but is now commonly used to refer to opioids, (Elkins 2018). However, the
term is no longer used in medical settings due to its association with illegal drugs (Labonville
2017).
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5. Opioid Overdose and Tolerance
While opioids can be used to relieve pain, opioids also affect the part of the brain that
regulates breathing. When someone takes high doses of opioids, it can lead to an overdose with
the slowing or stopping of breathing and sometimes death (Elkins 2018). Symptoms of opioid
overdose include confusion, delirium, frequent vomiting, pinpoint pupils, the inability to wake
up, intermittent loss of consciousness, breathing problems, respiratory arrest, and cold or bluish
skin around the lips or under the fingernails (AAC 2019). In 2011, the Centers for Disease
Control and Prevention (CDC) classified overdoses from prescription painkillers as an epidemic.
The leading cause of accidental death in the United States is due to drug overdoses. Opioids are
the most common drugs involved in those deaths (Schiller et al 2019).
Tolerance occurs when a higher dose of a drug is required to achieve the same
pleasurable effect delivered by an initial smaller dose. Drug tolerance develops in response to
repeated use over time (NIH 2017). A person’s tolerance to a drug changes their perspective on
the amount of the drug that they can safely handle. If drug tolerance declines unknowingly, drug
users are more likely to overdose. For example, former opioid users who have been recently
released from prison or have recently detoxed are more likely to overdose than new opioid users
(Kumar 2016).
B.

The Opioid Epidemic
1.

Chronic Pain and the Role of Opioids in Pain Treatment

Records of opium growth date back to 3400 B.C. when the Sumerians cultivated the
opium poppy in lower Mesopotamia. The Sumerians referred to it as Hul Gil, the "joy plant."
The use of opium spread slowly eastward from Mesopotamia and Greece. Initially, the use of
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opium was primarily linked to religion and mysticism. However, later accounts in medical texts
such as the ancient Egyptian Ebers Papyrus, describe medical uses for opium (Niewijk 2017).
In the seventeenth century, recreational use of opium became popular soon after smoking
tobacco became illegal in China. Opium dens, in which consumers bought and smoked opium,
spread across China and in other countries. England was the primary supplier of China’s opium
when China outlawed its use. Due to the profitability of opium, England attempted to prevent
the criminalization of opium. After opium became illegal in China, England continued to sell
opium, which led to the First and Second Opium Wars (Niewijk 2017).
In the nineteenth century, the first widespread problem with opioids developed in the
United States. Opioids were used in the early 1860s to treat wounded soldiers’ pain during the
American Civil War. The Union alone issued 2.8 million ounces of opium powder and tincture
and 10 million opium pills to their soldiers. Consequently, many soldiers developed opioid
addiction and dependency, especially to morphine. In 1856, the hypodermic syringe was
introduced, and by the 1870s, it was widely used to inject morphine. While medical journals
were filled with warnings about morphine addiction, many doctors were slow to heed the
warning due to inadequate education and/or a lack of other pain treatments (Trickey 2018).
In 1898, the Bayer Company was first to introduce commercialized heroin with the claim
it was less addictive than morphine. Heroin was ultimately found to be more addictive than
morphine, and the ensuing opioid epidemic led the U.S. government to place restrictions on
opioids in the 1910s and 1920s. These restrictions included making heroin illegal and requiring
that formal prescriptions be written in order to receive certain opioids and other narcotics
(Trickey 2018).
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Heroin use surged once again in the 1960s and 1970s in the United States, fueled in part
by Vietnam War soldiers who were exposed to heroin while fighting overseas (STAT 2017).
President Nixon responded by declaring a “War on Drugs” in 1971. In 1973, the Drug
Enforcement Agency was created by merging the Office for Drug Abuse Law Enforcement, the
Bureau of Narcotics and Dangerous Drugs, and the Office of Narcotics Intelligence in an attempt
to centralize federal efforts to control drug abuse. In the early 1980s, the heroin crisis evolved
into the “Crack Epidemic.” The War on Drugs policies were expanded in 1986 when Congress
passed the Anti-Drug Abuse Act of 1986, which allocated $1.7 billion to reduce drug activity
(Augustyn and Lotha 2018, HarvardX). Although the War on Drugs policies continue today, the
peak of this effort was in the 1980s.
2. How Opioids Rose to Prominence in Pain Treatment
i.

The Prevalence of Pain in the United States

Chronic pain is a prevalent medical condition in the United States. More than 30% of
Americans have some type of acute or chronic pain (Volkow 2016). In a recent report, the CDC
estimated that chronic pain affects 20.4% of adults and high-impact chronic pain affects 8.0% of
adults in the population. The prevalence of pain is higher among women and older adults in
addition to people who were previously but not currently employed, living in poverty, on public
insurance and living in rural areas. While the impact of chronic pain is often associated with
restrictions in daily activities, high impact chronic pain is debilitating, leading to “limitations in
major life domains, including work, social, recreational, and self-care activities” (CDC 2018).
ii.

Early Opioid Studies Show Low Addiction Risk

The high incidence of pain in the United States created an increased demand to manage
pain. Drugs, especially opioids, appeared to be a good solution. In 1980, Porter and Jick wrote a
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five-sentence letter to the editor of the New England Journal of Medicine. Published in the
correspondence section, the letter suggested that addiction was rare among their patients. Their
patients did not have a history of addiction and were being treated for acute pain in a hospital
setting (Collins 2018, Zhang 2017).1 Portenoy and Foley (1986) also suggested that the risk of
opioid addiction was low after observing 38 patients with chronic pain. Neither of these cases
focused on patients with non-malignant pain, and neither study was scientifically rigorous. Dr.
Jick’s letter was based on information collected by his graduate student, Porter. She had been
asked to note the number of addictions that occurred among their patients. Both the Jick and
Porter (1980) and the Portenoy and Foley (1986) observations were used as evidence that the risk
of addiction with opioid use was low. They also contributed to the perception that health care
providers were allowing patients to suffer when their pain could be safely treated. Widespread
dissemination of information from these observations lead to the rise of opioid prescriptions for
acute non-chronic pain.. (Jones et al 2018).
Clearly the published statements from Jick and Porter (1980) and Portenoy and Foley
(1986) overstated the safety of opioid prescription drugs. The impact of the addictive nature of
opioids is significant. The National Institute on Drug Abuse suggests that approximately 21% to
29% of individuals with opioid prescriptions to treat chronic pain misuse them and between 8%
and 12 % of these individuals develop an opioid use disorder (NIH 2019).

1

“Recently, we examined our current files to determine the incidence of narcotic addiction in 39,946 hospitalized
medical patients who were monitored consecutively. Although there were 11,882 patients who received at least one
narcotic preparation, there were only four cases of reasonably well documented addiction in patients who had no
history of addiction. The addiction was considered major in only one instance. The drugs implicated were
meperidine in two patients, Percodan in one, and hydromorphone in one. We conclude that despite widespread use
of narcotic drugs in hospitals, the development of addiction is rare in medical patients with no history of addiction.”
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iii.

Pain as a Vital Sign

Pain management policy in the United States during the late twentieth century reflected
both the current attitudes towards patients that suffered with pain and a rise in disabled war
veterans. Both factors led to a perception that pain was undertreated and to an increased focus
on treating pain. In an effort to reduce the perceived inadequate treatment of pain, the American
Pain Society (APS) campaigned for pain to be recognized as the 5th vital sign in 1996. Prior to
1996, the vital signs that were measured included body temperature, pulse rate, respiration rate,
and blood pressure. These vital signs were assessed with medical instruments. The goal of the
APS campaign was to ensure that pain assessment was recognized as an equally important
measure of patient wellbeing as the other four vital signs. In 1999, the VA Hospital System also
recognized pain as a vital sign (Koepke et al 2018). Initially, the campaign was widely
supported by regulatory organizations, medical societies, and pharmaceutical companies
(Bernard 2018).
The APS guidelines suggested that pain should be measured and recorded in a way that is
visible using unidimensional pain scales and carefully monitored by members of the health care
team (Bernard 2018). However, the interpretation of these guidelines became problematic
because a patient’s self-assessed pain level is subjective and may differ substantially among
patients.
This APS campaign to make pain the 5th vital sign had implications that were important
in contributing to the development of the opioid crisis. One of the most significant
consequences was the impact on the Joint Commission on Accreditation of Healthcare
Organizations (JCAHO), the hospital credentialing agency. The JCAHO agency taught
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healthcare professionals to assess and treat pain.2 They also required that pain scores be
documented (Koepke et al 2018, Alam and Juurlink 2016).
The APS campaign also affected the United States Hospital Consumer Assessment of
Healthcare Providers and Systems (HCAHPS) survey. The HCAHPS survey is a patient
satisfaction survey that facilitates reimbursement to US healthcare providers. It is used by the
Centers for Medicare and Medicaid Services (CMS) (Bernard 2018). Following the recognition
of pain as the 5th vital sign, a question was added to the survey that asked how well the hospital
staff was treating a patient’s pain. This question led to the unintended consequence of
encouraging more aggressive pain treatment in response to a patient’s self-reported numerical
pain scores. The aggressive pain treatment often came in the form of opioid prescriptions which
otherwise may not have been prescribed if physicians were not being assessed based on
responses to the survey’s pain treatment question. The responses to the survey were also used in
evaluating the amount of funding a facility received, thus creating an additional incentive to
adjust treatment to get high scores on pain management questions in the survey.
It has been suggested that the APS ‘pain as the 5th vital sign’ campaign has directly
contributed to the ongoing opioid epidemic in the United States. The American Medical
Association, the American College of Surgeons, JCAHO, The American Academy of Family
Physicians, and the Centers for Medicare and Medicaid services no longer support or advocate
the recognition of ‘pain as the fifth vital sign’ campaign. This pain management policy is seen
has one of the greatest mistakes in medical history (Levy 2018).

2

Pharmaceutical companies funded and wrote educational material for JCAHO regarding pain assessment and
management.
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iv.

Marketing for Opioids in the Pharmaceutical Industry

Pharmaceutical companies also played a role in causing the opioid epidemic by
aggressively marketing opioid pain medications. The most well know company was Purdue
Pharma. Following the widespread recognition of pain as the 5th vital sign by the medical
community and the increased acceptance of opioids to manage pain, the demand for opioid
medications increased. In 1996, Purdue Pharma introduced OxyContin to relieve pain as part of
an extensive marketing plan. As OxyContin sales increased from $48 million in 1996 to around
$1.1 billion in 2000, the high availability of OxyContin was associated with increased opioid
abuse. From 1996 to 2001, Purdue Pharma’s marketing plan included conducting forty national
pain-management and speaker-training conferences at resorts where more than 5,000 physicians,
pharmacists, and nurses attended. Purdue Pharma promoted OxyContin among primary care
providers for more liberal use, and by 2003, primary care providers made up almost half of all
physicians prescribing OxyContin. Purdue Pharma also promoted the idea that the risk of
addiction from OxyContin was extremely low (less than one percent) and cited Porter and Jick’s
(1980) note in the New England Journal of Medicine to support their claims (Van Zee 2009).3
v. A Summary of the Causes of the Opioid Crisis
Although the causes of the opioid crisis were multifaceted, primary factors were an
increased demand for pain treatment, two widely cited notes based on observations of patients
with acute and chronic pain underestimating opioid addiction risk, a recognition as pain as a vital
sign, and aggressive pharmaceutical marketing for opioid prescriptions.

3

After performing a bibliometric analysis of the Jick and Porter (1980) correspondence from its publication until
March 30, 2017, Leung et al (2017) conclude that it was “heavily and uncritically cited as evidence that addiction
was rare with long-term opioid therapy.” In particular, the authors found 608 citations of the correspondence and
noticed a sizable increase after OxyContin was introduced.
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As the opioid crisis has evolved, many of the participants responsible for increased opioid
use have admitted their role in the crisis. Dr. Jick was mortified that his note was used by
pharmaceutical companies to provide evidence that opioid use was safe and to promote their
opioid drugs. He later regretted publishing his 1980 letter to the editor. In 2017, the editor of the
New England Journal of Medicine added a cautionary statement to the Porter and Jick letter. The
statement warned readers of its misleading citation (Zhang 2017).4
As mentioned earlier, the acceptance of pain as a fifth vital sign has been seen as one of
the biggest mistakes in medical history. The APS campaign for ‘pain as the 5th vital sign’ lost
its support from regulatory organizations, medical societies, and pharmaceutical companies.
Both the American Medical Association (AMA) and American Academy of Family Physicians
(AAFP) removed pain as a vital sign in 2016. The AMA also publicly apologized for the
physicians’ role in the crisis due to their pressure to treat pain (Gart 2017).
In 2017, Purdue Pharma pleaded guilty to a felony charge of misbranding OxyContin
while marketing it as a safe and low addiction risk pain medication (Meier 2018). Three
executives pleaded guilty to a misdemeanor misbranding charge. The company and the
executives paid a combined $634.5 million in fines. However, Purdue Pharma’s legal problems
are not over. There are more than 2000 lawsuits against the company for its part in the Opioid
Crisis. On September 15, 2019, Purdue Pharma announced an agreement in principal to settle
the opioid litigation. Key requirements of the settlement are detailed on their website. All of
Purdue’s assets will be contributed for the benefit of the American public due to this settlement.
The settlement is estimated to provide more than $10 billion to address the opioid crisis,

4

On NEJM’s website, the Porter and Jick letter now has an editor’s note that reads, “For reasons of public health,
readers should be aware that this letter has been ‘heavily and uncritically’ cited as evidence that addiction is rare
with opioid therapy.”
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including the potential to provide millions of doses of life-saving opioid overdose reversal
medications. Finally, Purdue will use Chapter 11 reorganization to finalize and implement the
settlement agreement (Purdue Pharma 2019).
Although Purdue Pharma was the most well-known of the companies involved in the
opioid crisis, other pharmaceutical companies also face lawsuits. Recently, the drug
manufacturer, Teva Pharmaceuticals, and three drug distributors reached a settlement with two
Ohio counties for $260 million (Hoffman 2019). John Kapoor, the founder of a pharmaceutical
company, Insys Therapeutics, has recently been sentenced to 5 years and 5 months in prison for
leading a racketeering conspiracy. Kapoor oversaw a scheme to bribe medical professionals to
use his opioid-based pain reliever, Subsys (Chandna 2020). He is the first pharmaceutical
executive in the United States to be sentenced for his involvement in the opioid crisis.
3. Evolution of Opioid Substances Abused
While opioid prescription drugs paved the course for millions of Americans to develop
opioid addiction, opioid prescription drugs were not the only type of opioids abused. In 2010,
the FDA approved the reformulation of OxyContin, allowing Purdue Pharma to begin
distributing the reformulated product with the hope that it would be more difficult for abusers to
break the pill down for injection, snorting, chewing, and smoking (Burke 2011). However, the
demand for opioids did not decrease. Instead, the reformulated OxyContin was responsible for
many addicted individuals substituting illicit opioids, heroin or fentanyl (Cicero 2012). Heroin is
a cheaper and more easily manufactured semi-synthetic opioid alternative to expensive
prescription opioids. In 2017, an estimated 494,000 people in the United States (12-years or
older) reported heroin use in the past year (CDC 2019). The overdose deaths from heroin
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increased fivefold from 2010 to 2017 (CDC 2019). While heroin is still a relatively uncommon
drug in the United States, its use is growing in all demographic areas.
Drug overdoses from fentanyl have also increased rapidly during recent years. Beginning
in 2013, overdose deaths increased every quarter. During the years 2013 - 2014, the death rate
more than doubled, almost doubled during the years 2014 - 2015, and more than doubled
between the years 2015 - 2016 (Spencer et al 2019). Fentanyl is a synthetic opioid that is
cheaply manufactured and is easily available. Its potency is 50 to 100 times greater than
morphine. Fentanyl is available in a variety of forms such as tablets, powder, liquid, and
patches; therefore, it is frequently mislabeled or mixed with other drugs in the black market. As
obtaining prescription opioids becomes harder and opioid addicts substitute heroin, the exposure
to fentanyl increases. (Carney 2019)
Illegal drug networks have pushed heroin, fentanyl, and counterfeit pharmaceuticals into
suburban and rural areas in recent years. In the past, rural areas were less affected than urban
areas by drug trafficking. Recent trends suggest that there has been an increase in drug
trafficking in rural areas. On average, rural populations are older than urban populations, so
residents tend to have a greater demand for chronic pain management. Furthermore, chronic
pain and injury are more common in rural than in urban areas which has led to higher rates of
drug overdose deaths in rural counties, including deaths related to opioids. Opioid overdoses in
rural counties have increased at a rate more than three times the increase in urban counties
(Keyes et al 2014).
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4. The Current State of the Opioid Epidemic
i.

Trends in the Opioid Crisis

Chronic pain is a prevalent medical condition in the United States. As mentioned earlier,
the CDC estimated that chronic pain affects 20.4% of adults and high-impact chronic pain affects
8.0% of adults in the population. In spite of its prevalence and severity, chronic pain is complex
and difficult to manage. After increasing dramatically, opioid prescriptions reached their peak in
2012 at a rate of 81.3 prescriptions per 100 persons. Although the national prescribing rates had
fallen to 58.7 prescriptions per 100 persons by 2017, the variation in prescribing rates was
substantial among states and counties. For example, 16% of counties in the U.S. had prescribing
rates sufficient for every person in the county to have a prescription, and some counties had
prescribing rates that were seven times the national level (CDC 2018).
The rise in opioid abuse has been accompanied by deaths due to opioid overdoses. The
statistics highlight the seriousness of the opioid problem. Data from the CDC indicate an
approximate six-fold increase in opioid overdose deaths since 1999. More than 47,000 people
died of an opioid overdose in 2017, and 36% of those deaths involved prescription opioids (CDC
2018). Opioid related deaths have contributed to a decline in the U.S. life expectancy for the
third year in a row (Haskins 2019, Bernstein 2019).
The opioid crisis has also led to other problems. For example, many addicts share
needles when using drugs. It is estimated that a fourth of the new HIV infections each year in
the United States are due to sharing needles while injecting drugs. The increase of new HIV
infections affects public health negatively and costs millions of dollars for treatment (Sullivan
2005). In addition, because drug abuse is recognized as a major problem for society, tougher
penalties for drug offenses in the U.S. have led to a significant increase in individuals
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incarcerated (Chandler et al 2009). The rise in imprisonment has additional negative effects on
the economy as the labor force declines and public funds are reallocated to the prison system.
The economic burden of prescription abuse of opioids alone has been estimated to be $78.5
billion annually for the United States. This estimate includes healthcare costs, the cost of
addiction treatment, lost productivity, and criminal justice costs (NIH 2019, Florence 2016). The
burden for communities due to opioid use varies substantially throughout the United States and is
related to factors based on socioeconomic, demographic, and community level differences.
The latest report from the IQVIA Institute for Human Data Science showed that
prescription opioid dosage volume declined 17 percent in 2018, marking the single-largest
annual drop ever recorded within the United States. Although overdose deaths involving
prescription opioids have declined, overdoses from other types of opioids continue to show an
increase (Ingraham 2019).
ii.

Policies to Prevent Opioid Misuse

Efforts to prevent opioid misuse are ongoing and evolve with new information about the
epidemic. Strategies include decreasing both the supply of and the demand for opioids in
addition to reducing harm to drug users. For example, the majority of hospitals have adopted
policies limiting patient opioid prescriptions to seven days. Prescription drug monitoring
programs (PDMP) have also become widespread. These programs restrict patients from “doctor
shopping,” the process of going to multiple medical doctors until the desired prescription is
received. Pharmacies are also part of the solution through compliance programs, appropriate
drug disposal, patient education, security initiatives, and increasing naloxone access (NACDS
2019). Medical cannabis laws have also been shown to reduce opioid misuse. State medical
cannabis laws legalizing the use of medical marijuana are associated with both lower prescribing
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rates and significantly lower state level opioid overdose death rates (Bachhuber et al 2014, Wen
and Hockenberry 2018).
iii.

Treatments for Opioid Addiction

Even though opioid addiction is treatable, in practice, it is often untreated and stigmatized
(Chandler et al. 2009). Strictly cutting off the supply of an individual’s opioids is not an
adequate approach to help addicted individuals. In order for treatment to be effective, it must be
tailored to the individual patient as addiction often comes with other illnesses such as depression
or anxiety disorder. The most effective treatment for opioid addiction usually includes a
combination of therapy and medication (Dennis et al 2007). However, only 17.5% of people
with a prescription use disorder received individual treatment in 2016. Methadone,
buprenorphine, and naloxone are the three commonly used medications. Methadone, a longacting synthetic opioid agonist medication, can prevent withdrawal symptoms and reduce
craving in opioid-addicted individuals. Buprenorphine, a synthetic opioid medication, acts as a
partial agonist at opium receptors and is able to reduce or eliminate withdrawal symptoms.
Naloxone is an opioid antagonist. It binds to opioid receptors and can reverse and block the
effects of other opioids; therefore, it is used to temporarily reverse the effects of an opioid
overdose such as slowed or stopped breathing. Although highly effective, these medications are
underutilized. Less than 50% of treatment programs in the private sector offer these medications
and only a third of eligible patients actually receive them (NIDA 2018). In 2015, the Secretary
of Health and Human Services announced five initiatives to address the opioid crisis: 1) improve
access to treatment and recovery services; 2) promote the use of overdose-reversing drugs; 3)
strengthen our understanding of the epidemic through better public health surveillance; 4)
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provide support for cutting-edge research on pain and addiction; and 5) advance better practices
for pain management (NIDA 2018).
C. Summary
The introduction to this thesis has provided background information in which to
contextualize the opioid epidemic. The scope of studies needed to fully understand the opioid
epidemic includes research on addiction, opioids, pain management, policy, and treatment for
opioid abuse. An implication of this literature is that a successful solution to the opioid epidemic
must be multifaceted involving research efforts in many disciplines.
As mentioned previously, a significant measure of the seriousness of opioid addiction is
the number of overdose deaths. Despite the risk of addiction and overdose, opioids are
commonly prescribed to combat pain. This paper uses cross-sectional county and state level
panel data to examine the socioeconomic, demographic, and community level factors that are
important in explaining opioid overdoses.
Section II includes a review of the literature. Empirical studies that examine the factors
related to opioid overdose deaths are discussed. A theoretical model of rational addiction is
presented in Section III. Section IV develops two empirical models for an analysis of opioid
deaths based on state and county level data. The empirical results are also discussed. Section V
offers conclusions.
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II.

A Review of the Literature: Risk Factors Associated with Opioid Abuse
In a systematic review of factors related to opioid overdoses in the United States and

Canada, King et al (2014) organize opioid mortality risk factors into three broad categories that
include prescriber behavior, user behavior and characteristics, and environmental and systemic
determinants.
A.

Prescriber Behavior

The behavior of prescribers has been shown to play a key role in opioid-related overdose
deaths. Prescriber behaviors related to an increase in overdoses include prescribing opioids to
more patients, prescribing opioids to patients frequently, prescribing opioids in higher dosages
and prescribing more potent opioids such as methadone and oxycodone (King et al 2014).
Opioid prescribing varies greatly among physicians. Some studies suggest that prescriber
behavior is linked to prescriber characteristics. For example, a physician’s prescribing behavior
varies with the type of medical training received, resident specialty, or physician bias (Leventhal
et al 2019, Todd et al 1994).
1. Opioid Prescription Sales and High-Volume Prescribing
Empirical research suggests that opioid related mortality is associated with both the
number of patients receiving opioid prescriptions and how frequently (volume) a physician
prescribes opioids.
Opioid sales, substance abuse treatment admissions related to opioid pain relievers, and
opioid overdose deaths increased significantly from 1999 to 2009 (Paulozzi et al 2011b).
Paulozzi and Ryan (2006) examine opioid overdoses at the state level and find that the variation
in the availability of opioid painkillers is related to the spatial distribution of drug overdose
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deaths. States with lower opioid death rates have lower rates of both opioid pain reliever sales
and nonmedical use of opioid pain relievers (Paulozzi et al 2011b).
Dhalla et al (2011) examine volume prescribing behavior and find that opioid deaths are
concentrated among patients treated by physicians who prescribe opioids frequently. In addition,
a study by Kim et al (2016) suggests that patients receiving opioids from high-volume
prescribers have a higher probability of prescription overlap with other opioids and
benzodiazepines.
2. Opioid Dosage
As opioid prescriptions and sales increased, the prescribed dosages also increased (King
et al 2014). Research suggests that opioid prescriptions in high doses are associated with an
increased risk of opioid overdose deaths among patients receiving opioid prescriptions for pain.
Bohnert et al (2011) examined the records of patients with cancer, chronic pain, acute pain, and
substance use disorders. They analyzed the relationship between the maximum prescribed daily
opioid dose, dosing schedules, and the risk of opioid overdose death. Their results suggest that
the risk of opioid overdose is positively related to the maximum prescribed daily dose of opioid
medication. Gomes et al (2011) also compared the number of opioid overdose deaths among
patients treated with varying daily doses of opioids. Their results support those reported by
Bohnert et al (2011) and also suggest a strong association between the number of high dose
opioid prescriptions dispensed and opioid-related mortality.
3. Prescription of Methadone and Oxycodone
Prior to 1990, opioid prescriptions for weaker opioids such as codeine were commonly
used to treat pain. However, prescriptions using more potent opioids such as methadone and
long-acting formulations of oxycodone increased rapidly (Manchikanti et al 2008, Paulozzi
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2009). Paulozzi and Ryan (2006) examine state data and find that opioid mortality rates are
significantly correlated with the use of methadone and oxycodone.
Methadone is a long-acting synthetic opioid agonist medication that is used both to
relieve pain and to reduce or prevent substance abuse. It can prevent withdrawal symptoms and
reduce craving in opioid-addicted individuals. Although methadone dosing is challenging
because the difference between therapeutic and toxic levels is minimal, it is a cheaper generic
drug; therefore, physicians may prefer it for patients who use private or government sponsored
insurance (King et al 2014). Paulozzi et al (2012) examine the relationship between methadone
prescriptions and opioid overdoses. They find that the overdose death rate from methadone is
significantly greater than the overdose death rates from other types of opioid prescriptions.
Results from Webster et al (2011) support their conclusions. They find that although methadone
makes up less than 5% of opioid prescriptions, it is involved in one third of opioid overdose
deaths and 30% of all drug overdoses treated in emergency departments.
Oxycodone is a powerful opioid and a popular prescription drug among providers due to
its long-acting pain relief. It is the primary ingredient in OxyContin, one of the most abused
prescriptions (Juergens 2019a). Oxycodone prescriptions rose rapidly between 1991 and 2007,
increasing by 850%. Dhalla et al (2009) found that the increase in oxycodone prescriptions were
accompanied by a fivefold increase in oxycodone-related overdose deaths. As mentioned
previously, due to the widespread abuse of these prescriptions, the FDA approved the
reformulation of OxyContin in 2010 in order to make it more difficult for abusers to break the
pill down for misuse (Burke 2011). Havens et al (2014) find that abuse of the original extended
release formulation of oxycodone fell significantly after the reformulation of OxyContin.
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Additionally, they find no evidence that the reformulated extended release formulation was
substituted for the original extended release formulation.
4. Prescriber Characteristics
Empirical studies have examined the relationship between prescriber characteristics and
prescriber behavior. For example, the type of training and resident specialty of prescribers might
affect the dosage and the quantity of opioid prescriptions that they write. Leventhal et al (2019)
examine opioid prescribing practices of emergency physicians based on their level of training or
resident specialty. They compare milligram equivalents (MME) of morphine prescribed to
patients.5 Their results suggest that non-emergency department residents placed in emergency
departments prescribe larger amounts of opioids.
Other studies have analyzed how physician bias may influence perceptions of the severity
of a patient’s pain. Todd et al (1994) examine the difference between patient and physician
estimates of pain severity for Hispanics and non-Hispanic whites. They find no difference in the
severity of pain in Hispanic and non-Hispanic white patients or in the disparity between patient
and physician pain assessments. Their results imply that Hispanic and non-Hispanic white
patients are given the same prescriptions; therefore, there should be no difference in the
likelihood of opioid addiction due to a difference in opioid prescriptions. Tamayo-Sarver et al
(2003) find similar results when they examine pain prescriptions in a national sample of
emergency departments. Their analysis of data on pain prescriptions for black, Latino, and white
patients indicate no significant correlation between race and prescriptions. However, physicians
were less likely to prescribe opioids to blacks relative to whites and Latinos.

5

Morphine milligram equivalents (MME) or morphine equivalent doses (MED) are standard values based on
morphine and its potency when compared to another opioid drug (Labonville 2016).
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B.

User Behavior and Characteristics

The behavior and the characteristics of an opioid user may increase the risk of an opioid
related death. User behavior which may contribute to opioid overdoses includes diversion,
doctor or pharmacy shopping, and using multiple drugs. User characteristics linked to an
increase in opioid related mortality include mental health status and sociodemographic
characteristics (King et al 2014, Davis et al 2017).
1. Prescription Drug Diversion and Doctor or Pharmacy Shopping
Prescription drug diversion is “the unlawful channeling of regulated pharmaceuticals
from legal sources to the illicit marketplace” … it “includes transferring drugs to people they
were not prescribed for” (Wood 2015). Doctor or pharmacy shopping are two ways in which
prescriptions may be diverted. Doctor or pharmacy shopping occurs when patients visit more
than one doctor or pharmacy to obtain prescriptions. Although data restrictions make it difficult
to quantify the exact number of opioid overdoses in which diversion has played role, empirical
studies suggest that doctor or pharmacy shopping is associated with an increase in opioid deaths.
Hall et al (2008) examine the records of all West Virginia residents who died of
unintentional pharmaceutical overdoses in 2006. They find that pharmaceutical diversion was
linked to 63.1% of those deaths while doctor shopping was associated with 21.4% of them. They
conclude that a majority of overdose deaths in West Virginia were associated with the diversion
of prescription opioids and nonmedical opioid use. Peirce et al (2012) also examine drug
diversion in West Virginia. They compared living subjects receiving opioid prescriptions with
individuals who died from an opioid drug overdose for evidence of doctor and pharmacy
shopping. They find that the deceased subjects had a significantly higher number of doctor
shoppers (25.21% versus 3.5%) and pharmacy shoppers (17.84% versus 1.3%). They also find
22

that approximately 20.23% of doctor shoppers were also pharmacy shoppers and 55.60% of
pharmacy shoppers were also doctor shoppers. Their conclusions suggest the need for
prescription monitoring programs to provide more prescriber oversight.
McDonald and Carlson (2013) provide national estimates for doctor shopping. Their
study is unique in two ways. First, they point out that prior estimates of doctor shopping were
based on insurance claims or state drug monitoring programs. Using those types of data, doctor
shopping activity was estimated to occur with 0.2% - 13% of all opioid patients. Because doctor
shoppers often pay with cash to avoid being detected, McDonald and Carlson use a dataset that
includes all opioid prescriptions dispensed to individuals across all retail pharmacies. Second,
prior estimates of doctor shopping activity were based on the professional judgement of
physicians to define doctor shopping so the estimates had a lot of variability. To overcome this
problem, McDonald and Carlson developed a mathematical model that grouped patients by how
many different prescribers they had visited within the past year. This approach led to an
“extreme” group of 135,000 likely doctor shoppers. These individuals visited 10 different
doctors on average and obtained approximately 32 opioid prescriptions in the prior 10 months.
They find that although doctor shoppers make up 0.7% of all patients receiving opioid
prescriptions, they purchase approximately 2% of all opioid prescriptions.
Simeone (2017) examines doctor shopping activity with state data and finds that the
number of diverted prescriptions declined from 1.75% of all prescriptions in 2008 to 1.27% of all
prescriptions in 2012. In addition, the number of morphine equivalent milligrams declined from
2.95% of total metric tons in 2008 to 2.19% of total metric tons in 2012. They note that their
empirical analysis provides evidence that efforts to control diversion such as prescription
monitoring programs have been effective.
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2. Polydrug Toxicity
Polydrug use refers to using more than one drug at a time to intensify the effects of a
single drug. King et al (2014) point out that many opioid related deaths also involve other drugs
such as prescription medications for sedatives, additional opioid prescriptions, alcohol, and illicit
drugs. They suggest that opioid overdose may be “part of an epidemic of multidrug mortality”
(p. 37).
Numerous studies have linked polydrug toxicity and opioid abuse. Piercefield et al (2010)
find that drug overdose deaths often involve multiple substances, and the most common
substance is prescription opioids.

Over half of all alcohol-related emergency room visits

involved illicit and prescription drugs in 2011 (Juergens 2019b). Esser et al (2019) analyzed data
from individuals who responded to questions about prescription opioid misuse and alcohol
consumption. Their research suggests that prescription opioid misuse was more prevalent among
binge drinkers than nondrinkers and that one fifth of prescription opioid overdose deaths also
involve alcohol. Slavova et al (2017) find that many fatal fentanyl overdoses are associated with
heroin adulterated with fentanyl and suggest that the lack of routine emergency department drug
testing likely results in underreporting non-fatal overdoses involving fentanyl and other synthetic
drugs.
3. Mental Health Status
Davis et al (2017) examine the relationship between mental health disorders due to mood
and anxiety and prescription opioid use. They estimate that 18.7% of Americans with mental
health disorders use prescription opioids and adults with mental health conditions receive 51.4%
of the total opioid prescriptions in the United States each year. They also find that having a
mental disorder significantly increases the likelihood of treating pain with opioids (18.7% versus
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5.0%; p < 0.001). Because more than half of opioid prescriptions in the United States go to the
16% of Americans with mental health disorders, their results imply that improving pain
management among the population with mental health disorders is critical to reducing national
dependency on opioids. An association between opioid use and suicide has also been found in
empirical studies. Ilgen et al (2016) examine opioid dosage as a potential factor for an increased
risk of suicide among patients with chronic pain. They find that the risk of suicide rises with an
increase in the dose of opioid prescriptions.
4. Sociodemographic Characteristics
Opioid related deaths are related to sociodemographic characteristics such as age, race,
ethnic background, gender, and socioeconomic status. Deaths from opioid use are also related to
whether opioid users reside in urban or rural areas.6
Many empirical studies have examined the importance of sociodemographic factors in
assessing the risk of opioid deaths. Paulozzi et al (2011a) examine the relationship between age,
race, ethnicity, sex, and opioid overdose rates. Although their results suggest that opioid
overdose death rates are highest among individuals 35 to 54 years old, they conclude that
differences in race, ethnicity, or demographics cannot fully explain state variations in opioid
prescription sales or in nonmedical use of opioids.
King et al (2014) evaluate 22 studies that focused on sociodemographic differences.
These studies suggest that, generally, opioid deaths are “higher among men, non-Hispanic
Whites and American Indian/Alaska Natives, middle-aged individuals, those living in rural areas,

6

Because socioeconomic factors are significantly correlated with urban or rural residential status, empirical studies
often examine both characteristics. A more complete discussion of the relationship between urban and rural
residential status and opioid overdose risk is found in the last section on environmental and systemic
determinants.

25

and those of lower socioeconomic status” (p. 36). However, they note “considerable
heterogeneity” with these overall patterns. Research also suggests that sociodemographic trends
vary over time and with the specific drug.
Empirical research by others support King’s conclusions. Green et al (2010) provide
evidence that an individual’s age and race may be correlated with abuse of a specific drug. They
find that heroin-only deaths are higher among non-whites, are more likely to involve alcohol or
cocaine, and typically occur in public locations and large cities. Alternatively, prescription
opioid-only deaths are more likely to involve other medications and occur in suburban or rural
locations, compared to heroin overdose deaths from methadone. Jones et al (2015) find that nonHispanic whites experienced higher methadone overdose death rates than other racial or ethnic
groups. Alexander et al (2018) find that the opioid epidemic was primarily driven by heroin
from 1979 to the mid-1990s. Both white and black populations were affected. During the mid1990s to 2010, the increase in opioid mortality was driven by natural and semi-synthetic opioids
among whites; however, there was no increase in mortality among blacks. Heroin and synthetic
opioids have been primarily responsible for the increase in opioid related mortality for both
populations from 2010 to the present.
Gender also plays a role in the risk of opioid overdose. While more men die from drug
overdoses than women, some studies indicate that the percentage increase in both opioid abuse
and deaths is greater among women. Jones et al (2015) find that men experience higher
overdose death rates than women. Mack et al (2013) find that opioid related overdose deaths for
women increased fivefold between 1999 and 2010, while opioid overdose deaths among men
increased 3.6 times. They also find that emergency department visits related to misuse or abuse
of opioids among women more than doubled between 2004 and 2010. Binswanger et al (2013)
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used data from the prison system in the state of Washington to examine the factors responsible
for mortality following release from prison between 1999 and 2009. They find that opioids were
related to 14.8% of all deaths and that women experienced an increased risk of an opioid-related
overdose.
C.

Environmental and Systemic Determinants

Empirical studies suggest that environment and systematic factors may be related to the
risk of opioid-related deaths. Environmental and systematic factors include area urbanization or
socioeconomic status (SES), geography, economic opportunity, and interventions which focus on
policies to reduce the supply of and the demand for opioids and to reduce harm. Other factors,
such as state laws on Cannabis policy, may have an indirect impact on opioid overdoses.
1. Urbanization or Socioeconomic Status
Urban and rural residential status may be a factor in predicting the risk of opioid
addiction. Guy et al (2017) suggest an association between higher opioid prescription rates and
rural residence. Lister et al (2019) examine opioid prescribing and opioid-overdose death rates
in Michigan to compare urban and rural counties. They find that urban counties have a high
rates of opioid overdose deaths, but rural counties have higher rates of opioid prescribing.
Paulozzi (2006) finds that the majority of publicity has focused on opioid abuse in rural areas
such as Appalachia and that higher prescription drug overdose death rates have been reported in
more rural areas within states. However, Rigg et al (2018) find that opioid overdose death rates
are not disproportionately higher in rural areas. They suggest that infrastructural,
socioeconomic, and social factors have contributed to the higher prevalence of opioid-related
mortality in rural areas. For example, they note that limited access to addiction treatment,
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underdeveloped prevention workforces, lack of harm reduction programs, and health care
shortages hinder rural communities from properly addressing the opioid crisis.
The association between rural residence and opioid prescriptions may also be linked to
doctor and/or pharmacy shopping and pill mills within rural communities. “Pill mill” is a term
that describes an illegal operation where a doctor, clinic, and/or pharmacy prescribes or sells
prescriptions inappropriately (Rigg et al 2010). Hall et al (2008) suggest that many individuals
have been successful in doctor shopping and that pill mills have been effectively distributing
opioids to the public, especially in rural communities.
Peters et al (2019) use county level data to analyze opioid overdoses during the subperiods, 2002-2004, 2008-2012, and 2014-2016. They find that the type of opioids abused varies
regionally. They suggest that the opioid crisis involves several epidemics occurring at the same
time. They identify three distinct epidemics (prescription opioids, heroin, and prescriptionsynthetic opioid mixtures) and a syndemic which involves a population with more than one
epidemic. Syndemics are a set of linked health related issues that interact with each other and
cluster in population subgroups, creating a greater burden for those subgroups (Shiel 2018).
Peters et al (2019) find that each epidemic and syndemic affects different populations. The
prescription opioid-related epidemic is associated with access to opioids from pharmacies and is
most common in rural southern states. It affects urban and rural counties that have been “left
behind” the rest of the nation. The “left behind” counties are former agricultural and
manufacturing communities that have been in decline since the 1990s. These communities are
less populated and more remote, older and mostly white, and have a history of drug abuse. On
the other hand, the counties most affected by heroin and the opioid syndemic are more urban,
connected to interstates, ethnically diverse, and more economically stable. Peters et al (2019)
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suggests that their research implies that multiple types of policies must be used to address the
regionally diverse distinct types of epidemics.
The latest CDC report by the National Center of Health Statistics (Hedegaard et al 2019)
on urban-rural differences in drug overdose rates indicates that drug overdose deaths increased in
both urban and rural counties during the period 1999 to 2017. However, the urban-rural
differences in overdose death rates vary over time and by the type of drug involved. The
following paragraph summarizes their conclusion:
From 1999 through 2003, rates were higher in urban than in rural counties. Rates were similar
from 2004 through 2006, then higher in rural counties from 2007 through 2015. In 2016 and
2017, age-adjusted rates of drug overdose deaths were higher in urban than in rural counties. In
2017, the rates of drug overdose deaths involving heroin, synthetic opioids other than
methadone, and cocaine were higher in urban counties than in rural counties. In contrast, the
rates of drug overdose deaths involving natural and semisynthetic opioids and involving
psychostimulants with abuse potential were higher in rural counties than in urban counties. (p. 5)
2.

Geography

Geographic variation in opioid prescribing patterns and opioid overdose death rates exists
within the United States. Schieber et al (2019) use state level data from 2006 to 2017 to analyze
changes in opioid prescribing practices over time and how the changes are distributed across
states. They focus on six key prescription measures: “annual amount of opioids prescribed in
morphine milligram equivalents (MME) per person; mean duration per prescription in days; and
4 separate prescribing rates—for prescriptions 3 or fewer days, those 30 days or longer, those
with a high daily dosage (≥90 MME), and those with extended-release and long-acting
formulations” (p. 1). They find an increase in the mean duration and prescribing rate for longterm prescriptions of opioids but a decline in the amount of opioids prescribed per person and in
the prescribing rate for high-dosage prescriptions, short-term prescriptions, and extended-release
and long-acting formulations. They point out that although some decreases were significant, the
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results remained high. They also find significant variability (2- to 3-fold) in 5 of the 6
prescribing measures among states.
The most recent report on geographical variation in opioid related deaths by the CDC
uses data from 2017. During this year, 70,237 drug overdose deaths occurred in the United
States. The report indicated a significant increase of 9.6% in the age-adjusted rate of overdose
deaths from 2016 (19.8 per 100,000) to 2017 (21.7 per 100,000). During 2017, 47,600 overdose
deaths involved opioids (67.8% of all drug overdose deaths). Synthetic opioids (other than
methadone) were the primary opioids abused. The variability in drug overdose rates as
summarized in the report (online) follows:
In 2017, the states with the highest rates of death due to drug overdose were West
Virginia (57.8 per 100,000), Ohio (46.3 per 100,000), Pennsylvania (44.3 per 100,000), the
District of Columbia (44.0 per 100,000), and Kentucky (37.2 per 100,000).
States with statistically significant increases in drug overdose death rates from 2016 to
2017 included Alabama, Arizona, California, Connecticut, Delaware, Florida, Georgia, Illinois,
Indiana, Kentucky, Louisiana, Maine, Maryland, Michigan, New Jersey, New York, North
Carolina, Ohio, Pennsylvania, South Carolina, Tennessee, West Virginia, and Wisconsin.
Although they focus on county data and rural-urban residence, Peters et al (2019) suggest
that regional differences in opioid overdose mortality vary with the type of opioid. As mentioned
earlier, three distinct epidemics (prescription opioids, heroin, and prescription‐synthetic opioid
mixtures) and a syndemic are identified. They describe regional differences for each epidemic
and syndemic. The prescription drug epidemic is concentrated in rural southern states where
access to opioids involves local pharmacies. They point out that even though prescription drug
overdose mortality from pharmaceuticals reached the highest level nationwide in 2013 and
declined afterward, prescription opioids still present a problem in some areas. The heroin
epidemic is most severe in western and Midwestern states with urban areas close to interstates
with heavy drug trafficking, especially those used by cartels bringing in heroin from Mexico.
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The synthetic opioid epidemic is most pronounced in urban areas in the Northeast. They also
point out that these synthetic drugs are often mixed with heroin or cocaine. Finally, multiple
opioid epidemics exist together (a syndemic) in areas of the country where the opioid crisis
began, such as Kentucky, Ohio and West Virginia.
3. Economic Opportunity
Many empirical studies examine the relationship between economic opportunity, opioid
prescriptions, and opioid abuse. Ghertner et al (2018) note that individual characteristics
associated with opioid abuse include having low income, being uninsured, or receiving
Medicaid. However, they point out that even though the individual level relationship is clear, the
association between the level of opioid abuse and economic conditions in a community has not
been fully examined.
Empirical research results in studies of the relationship between economic conditions and
opioid abuse are mixed. Guy et al (2017) find that higher levels of unemployment are positively
associated with higher levels of opioid prescriptions in county level data. They also find
substantial variation in opioid prescribing patterns suggesting a lack of agreement on appropriate
prescribing practices. Hollingsworth et al (2017) find that an increase in the county
unemployment rate by one percentage point is associated with a 3.6% increase in the opioid
death rate. Some studies explore evidence of reverse causality, that is, that opioid abuse has a
negative impact on labor market conditions. Krueger (2017) finds a decline in labor force
participation in areas with higher opioid prescriptions. Similar to Krueger, Harris et al (2019)
suggest that per capita opioid prescriptions have a significant negative effect on the labor force
participation rate, employment-to-population ratio, and unemployment rate. Aliprantis et al.
(2019) also find a strong negative link between opioid prescription rates and labor force
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participation when using county level employment data. They estimate that prescription opioids
account for 44% of the decrease in male labor force participation from 2001 to 2015 in the U.S.,
with less educated men most affected. Ghertner and Goves (2018) explore the relationships
between three measures of economic opportunity (poverty rates, unemployment rates, and the
employment-to-population ratio), two measures of the prevalence of prescription opioids (retail
opioid sales and Medicare Part D opioid prescriptions) and two measures of substance use (drug
overdose deaths and opioid-related hospitalizations) using county level data. Their results
indicate that overall, the opioid crisis has a greater negative impact on areas with lower economic
activity. However, they note that the extent of the relationship varies with the region of the U.S.
They point out that “counties differ in their economic, demographic, cultural, and political
contexts” and further note that these factors may explain much of the diversity in the relationship
p. 8). They also note that one limitation of their study is that it does not find a causal relationship
between economic opportunity, the prevalence of opioids, and substance use.
Papers by Ruhm (2018) and Currie et al (2018a) contribute to the issues raised by
Ghertner and Goves (2018). Ruhm (2018) uses county level data from 1999-2015 to examine the
contribution of the deterioration in medium-run economic conditions versus changes in the drug
environment in explaining drug fatality rates. He finds a weak relationship between economic
decline and drug mortality rates which is mostly explained by confounding factors. He finds that
the risk of drug deaths varies over time and across population subgroups in a way that is
consistent with the availability and cost of drugs. Currie et al (2018a) examine the direction of
the casual effect in the relationship between opioid prescriptions and employment. They use
quarterly county level data on all opioid prescriptions filled at U.S. pharmacies from 2006 to
2014. Their analysis includes three parts. Initial regressions examine how the employment-to-
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population ratio within an area changes as prescription rates vary. They do not find a significant
relationship between changes in the per capita opioid prescriptions and changes in the
employment-to-populations ratio. They also estimate models of the effect of per capita opioid
prescription rates on employment-to-population ratios, using opioid prescriptions for the elderly
as an instrument for opioid prescriptions for younger ages, and models of the effect of
employment-to-population ratios on opioid prescription rates using a shift-share instrument.
Their results suggest that no simple causal relationship exists between economic conditions and
opioid abuse. In a separate article, Currie and Schnell (2018b) point out that poor economic
conditions are not responsible for the opioid epidemic. They also conclude their article with the
statements below:
What this means is that we must look at the opioid epidemic for what it is: a self-inflicted perfect
storm that arose from a combination of newly available opioids, new attitudes about the
importance of pain management, loose prescribing practices, and a lack of professional
accountability. The solution to the problem must lie in addressing some of these root causes.
(p. 4)
4. Interventions
Policy responses to the opioid epidemic include national, state, and community level
efforts to reduce both the supply and demand for opioids and to reduce harm. More education
about opioids for providers, patients, and the public at the national level is one example. King et
al (2014) discussed several studies that provide evidence that the guidelines, policies, and
consensus statements about how to manage pain played a role in the number of opioid-related
deaths. In 1997, as opioids were encouraged to treat chronic pain, opioid-related mortality
increased; however, new guidelines in 2007 with warnings about appropriate opioid dosages
were followed by a reduction in opioid deaths. Prescription Drug Monitoring Programs at the
state level is another example. Prescription Drug Monitoring Programs restrict the availability of
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opioids by discouraging patients from doctor shopping and providers from high-volume
prescribing. All states but Missouri have legislation authorizing the creation and operation of a
PDMP. Interact for Health, an independent philanthropic foundation that serves the Greater
Cincinnati area, represents a community response to the opioid epidemic. The foundation
developed an education campaign to reduce the stigma associated with opioid addiction, set up a
regional hotline, and provides funding for harm reduction strategies such as naloxone
distribution (Chubinski and Lydenberg 2020).
The evidence on the success of various interventions is mixed. Doleac et al (2019)
examine recent research on policies designed to decrease opioid abuse and opioid overdose
deaths. They focus on studies that attempt to quantify the casual effects of the policies on opioid
abuse and mortality. They point out that limiting the supply of opioids yet providing care for
individuals who need the medication involves tradeoffs. For example, PDMPs can reduce
opioid-related mortality, but they may also induce opioid users to substitute illicit opioids such as
heroin. Additionally, harm reduction strategies are associated with positive outcomes for some
but encourage risker opioid use among others.
Doleac et al (2019) also notes that average effects sometimes mask important differences
across states. For example, state laws regarding PDMPs vary. Some state laws require that
doctors access prior prescriptions given to patients before writing a prescription; on the other
hand, some states require only that information on prior prescriptions be provided. If a state
requires the use of information on prior prescriptions, then the law is a “must-access” PDMP.
Meara et al (2016) examine the impact of a variety of state policies on the opioid prescriptions
given to Medicare patients. They find that state policies such as PDMPs do not reduce opioid
prescriptions. However, Buchmueller and Carey (2018) distinguish between states that require
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that doctors access PDMP data and those states that do not. They find that must-access PDMPs
significantly reduce measures of opioid misuse while voluntary PDMPs did not have a
significant effect. Ayres and Jalal (2018) use county level panel data on all opioid prescriptions
in the United States to determine the effects of policies such as PDMPs. They also find that
PDMPs are most effective in reducing prescription rates if their use is required.
Other policies may have an impact on opioid use or opioid prescribing practices even
though they were not put into place with that specific goal. For example, many states have
decriminalized cannabis while some states have passed legislation allowing the use of medical or
recreational cannabis. Bachhuber et al (2014) find that state laws allowing medical cannabis are
associated with significantly lower opioid overdose death rates. Livingston et al (2017) compare
changes in the level of monthly opioid-related overdose deaths before and after Colorado
legalized recreational cannabis. They find that legalization of recreational cannabis sales resulted
in a 0.7 deaths per month decrease in opioid-related overdose deaths. Bradford et al (2018) also
find that medical cannabis laws are associated with significant reductions in opioid pain reliever
prescribing in the Medicare Part D population. Wen and Hockenberry (2018) analyzed the
relationship between the state implementation of medical and recreational marijuana laws, opioid
prescribing rates, and spending among Medicaid enrollees. Their study suggested that medical
marijuana laws are associated with a 5.88% decrease in opioid prescribing and recreational
marijuana laws are associated with a 6.38% decrease in opioid prescribing.
Ruhm (2018) points out that many empirical studies have been done on the effectiveness
of a variety of policies on opioid abuse and opioid mortality. He mentions policies associated
with medical marijuana, abuse-deterrent drug formulations, Naloxone availability, Medicare Part
D, the availability of substance abuse treatment, advertising, and state policies influencing the
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availability of prescription opioids. However, he concludes that each of these polices explain, “at
most, only a small portion of the overall change in overdose deaths” (p.5).
A review of the literature suggests that understanding the opioid epidemic is complex and
that effective policies to reduce opioid abuse must have an impact on prescriber behavior, user
behavior. and the environment. The policies must also be multifaceted and tailored to allow for
regional differences.
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III.

Theoretical Model
Because addiction is a chronic disease, it is related to theories in health economics. The

most well-known theories that serve as a basis for the empirical work that follows are
Grossman’s (1972) model of the demand for health and Becker’s and Murphy’s (1988) model of
rational addiction.
A.

The Production of Health

Grossman (1972) developed a model to explain an individual’s health. Grossman begins
by assuming that people derive utility from health and a composite of all other goods. The utility
function is:
Ut = Ut (Ht, Gt)
where Ht equals the stock of Health
and Gt equals all other goods.
Health is modeled as a production process. The production function of health summarizes
the relationship between health inputs such as medical care and lifestyle and health outcomes
such as life expectancy. The model treats investment in one’s stock of health as a form of
investment in human capital. Similar to other types of capital goods, the stock of health must be
maintained by making investments in health that exceed the amount by which health stock
deteriorates over time. The change in health stock can be expressed as gross investment in
health less depreciation of existing health stock which can be written as:
∆Hj = Hj, t+1 – Hjt = Ijt – ∆jtHjt
where ∆Hj equals net investment in health for individual j
Hj, t+1 equals health stock at time t+1
Hjt equals health stock at time t
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Ijt equals investment in health for individual j at time t, and
∆jtHjt equals the depreciation of health stock, where ∆jt equals the annual rate of
depreciation in individual j’s health stock.
Gross health investment (I) is a function of medical services (M) and the time devoted to
the production of health (T). Individuals with more human capital (C) are more efficient
producers of health. Grossman also assumes that depreciation in health is related to age (A) and
behavioral factors (B) such as alcohol consumption, smoking, and obesity which negatively
impact health, as well as others, such as good nutrition and exercise, which have a positive effect
on health. The behavioral input also includes chemical dependency and addiction which lead to
a deterioration in health stock.
The gross investment in health function may be written as:
Ijt = Ijt (Mjt, Tjt, Cjt, Ajt, Bjt).
B.

Rational Addiction

Behavioral factors that involve addictions to goods such as cigarettes, alcohol, and illicit
drugs are inputs in the production of health that have a negative impact on health status.
However, if addictive goods change the utility function of individuals, preferences may not be
time-consistent. Becker and Murphy (1988) develop a model in which individuals rationally
choose to consume addictive goods. Their theory is based on the assumption that individuals
incorporate all available information into their calculations of utility and that they are aware of
the addictive properties that may change their future preferences. Therefore, preferences are
time-consistent in their model. Current consumption increases the desire for future consumption,
and, as tolerance increases, the need to consume additional quantities of the addictive good in
order to achieve the same effect. The rational addict considers both the benefits and the harmful

38

consequences when choosing the level of consumption of the addictive good each period. Their
model implies that addiction is more likely in individuals who discount the future heavily, that is,
these individuals focus less on the future effects from current consumption choices.7
Becker et al (1991) extend Becker and Murphy’s model by adding addictive capital stock
to the utility function. In this model, consumption of the addictive good leads to addictive
capital stock that reinforces the desire for consumption of the addictive good as it makes future
consumption more pleasant. For example, an individual may begin smoking cigarettes knowing
its addictive properties. The initial cigarette may be unpleasant, but the experience becomes
more pleasant over time. The repetitive use of cigarettes reinforces the individual’s demand for
the addictive good. As the addictive capital stock grows, current consumption of the addictive
good increases. The smoker will want to smoke more and more. Addiction develops when
individuals experience withdrawal symptoms as they stop consuming cigarettes.
Models of addictive behavior have implications for the development of optimal public
policy solutions. The models above imply that since individuals take all information into
account before deciding to consume an addictive good, any expected increase in price will
decrease current consumption. Therefore, government policy can be used to reduce tobacco
consumption by increasing cigarette taxes. However, if the decision to consume addictive goods
is rational, an implication of these models is that government regulatory policy towards addictive
goods should depend only on interpersonal externalities. Gruber and Köszegi (2001) extend
Becker and Murphy’s model by assuming inconsistent preferences as individuals make decisions
about smoking. In this case, current levels of consumption of the addictive good may be too

7

Although the assumption of rational choice may seem restrictive, some empirical studies offer support for Becker
and Murphy’s model (Bentzen et al 1999)
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high because individuals underestimate the ability to stop smoking in the future. In this case,
optimal government policy solutions should consider both the externalities on others and the
internalities on the addict. This model is especially relevant for highly addictive substances such
as illicit drugs (Henderson 2018).
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IV.

Empirical Model
Theoretical models and empirical studies suggest that prescriber behavior, user behavior

and characteristics, and environmental and systemic factors play a key role in determining opioid
addiction. The opioid overdose mortality rate is the most commonly used measure of opioid
addiction in the empirical literature. This paper develops empirical models based on state and
county data to investigate the relationship between variables used to measure prescriber
behavior, user behavior and characteristics, and environmental and systemic factors and opioid
overdose deaths. For each level of analysis, the variables used in the empirical model and data
are described in the first section followed by a discussion of the empirical results in the second
section.
A. State Level Analysis
1. Data
The first empirical model uses state level panel data for the years 2014-2015 to examine
factors related to opioid overdose deaths in the United States. Only the states that had values for
all of the variables used in the empirical model are included in the analysis. The states include
Arizona, Arkansas, Colorado, Florida, Georgia, Hawaii, Iowa, Kentucky, Maine, Maryland,
Massachusetts, Michigan, Minnesota, Nebraska, Nevada, New Jersey, New Mexico, New York,
North Carolina, Oregon, Rhode Island, South Carolina, Texas, Vermont, Virginia, Washington,
West Virginia, and Wisconsin. There are 56 observations used in this study. All of the data
excluding the cannabis law data was obtained from the State Health Access Data Assistance
Center (SHADAC). Data for cannabis laws was gathered from a historical timeline on
ProCon.org.
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2. Model Specification and Regression Results
As discussed earlier, previous research suggests that prescriber behavior, user behavior
and characteristics, and environmental and systemic factors are related to opioid overdose
mortality. Proxies for each of these factors are used to develop the empirical model.
Prescription sales of oxycodone (PSO) and hydrocodone (PSH) per 100,000 persons are
included as variables to measure prescriber behavior within a state. Sales of both drugs increase
access to opioids and make opioid addiction more likely. Both variables are expected to be
positively associated with opioid overdose deaths. (Paulozzi et al 2011).
Four variables are used as measures of user behavior and characteristics. The variables
include the percentage of individuals in the civilian non-institutionalized population with at least
one visit to the emergency department during the past twelve months (ED), binge drinking
behavior measured as the percent of adults consuming four (women) or five (men) or more
drinks on one occasion during the past 30 days (BD), firearm suicides per 100,00 persons (SUI),
and preventable hospitalizations per 100,000 persons (PH). Potentially preventable
hospitalizations are admissions to a hospital for certain acute illnesses or worsening chronic
conditions that might not have required hospitalization if the condition been managed
successfully by a primary care provider (Moy et al 2013). This measure may also be interpreted
as the tendency for individuals to overuse emergency rooms and urgent care in place of primary
care (Brumley et al 2007).
The rate of emergency department visits is expected to be positively associated with
opioid overdose deaths. Prior studies have identified frequent visits to the emergency department
as a marker for opioid abuse. The frequency of emergency department visits has been linked to
nonmedical opioid use, drug diversion and poorly managed pain. Brady et al (2015) find a
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strong association between the rate of emergency department visits and an increased risk for
overdoses from prescription drugs.
Theory suggests that the net effect of binge drinking on opioid overdose deaths is
ambiguous because alcohol may be a complement to or a substitute for opioid use. Esser et al
(2019) find evidence of a complementary relationship as binge drinkers were almost twice as
likely as nondrinkers to misuse prescription opioids.
States with a greater number of firearm suicides and preventable hospitalizations are
expected to have more opioid overdose deaths. Both variables are associated with mental
disorders, chronic pain, and substance abuse. (Meiman et al 2015; Ilgen et al 2016; Martin
2018).
Four variables are used to measure environmental and systemic factors. The variables
include the unemployment rate (UR), the amount of state public health funding per person (F),
the state excise tax on cigarettes (CT) and the existence of laws allowing medical or recreational
cannabis (C).
The net effect of the unemployment rate on opioid overdose deaths is ambiguous.
Theoretically, as the unemployment rate increases and economic conditions decline, an increase
in opioid abuse and overdoses would be expected. However, as discussed earlier in the review of
the empirical literature, evidence on the relationship between the unemployment rate and the
opioid overdose rate is mixed (Currie and Schnell 2018). Some studies find a positive
relationship between the unemployment rate and opioid overdose deaths while other studies find
that the relationship between economic conditions and opioid deaths is weak once the
availability and cost of drugs are considered. Additional studies also find evidence of reverse
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causality between these two variables, that is, opioid abuse has a negative impact on the
unemployment rate (Harris 2019).
The net effect of state public health funding per person on opioid overdose deaths is
ambiguous. While state public health public funding can be used to increase measures to combat
the opioid epidemic, public health funding also increases access to health care and pain
prescriptions such as opioids.
In theory, the impact of the state excise tax on cigarettes on the opioid overdose death
rate is ambiguous, depending on whether cigarettes serve as a substitute or a complement to
opioid use. If cigarettes are a substitute for opioids, an increase in the excise tax on cigarettes
would reduce cigarette consumption and increase opioid abuse and overdoses. If cigarettes and
opioids are complements, an increase in the excise tax on cigarettes would have the opposite
effect on opioid overdoses. There is some empirical research to suggest that cigarettes and
opioids are complements. Michna et al (2004) find that cigarette smoking is associated with a
higher risk of opioid abuse. Chun et al (2009) studied the smoking behavior of patients being
treated for opioid addiction and find that heavier smoking activity is associated with a stronger
drug addiction.
A dummy variable is used for state laws which allow the use of medical or recreational
cannabis (1 = the use of medical marijuana or recreational cannabis is legal). Opioid overdose
deaths have been driven by prescriptions to treat chronic pain. Because medical cannabis is used
to treat pain, states in which medical cannabis is legal may have lower rates of opioid abuse and
overdose deaths. Bachhuber et al (2014) find that medical cannabis laws are associated with
significantly lower state level opioid overdose mortality rates. Additional studies have examined
opioid overdose death rates in states that have legalized marijuana for recreational use such as
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Colorado, which experienced a 7% drop in opioid related mortality. However, one meta-analysis
suggests that while legalizing marijuana is associated with a small reduction in opioid
prescriptions, the impact on opioid overdose deaths is inconsistent (Chihun and Li et al 2019).
Because panel data is used, a dummy variable for the year (0 = 2014; 1 = 2015) is
included to capture time fixed effects, that is, the possibility that factors not captured in the
model affect all variables and vary from one year to year.
An explanation of the variables and descriptive statistics is in Table 1. Descriptive
statistics are computed from data in 28 states over two years, 2014-2015. The sample includes 56
observations.
Table 1
Label

Variable

Mean

Y

Natural and semi-synthetic opioid overdose deaths
excluding heroin per 100,000 persons
Prescription sales of oxycodone per 100,000
persons
Prescription sales of hydrocodone per 100,000
persons
Unemployment rate
Firearm suicides per 100,000 persons
Preventable hospitalizations per 100,000 persons
Percent of civilians who visited the emergency
department during the past year
Percent of adults binge drinking during the past 30
days
Presences of legal medical or recreational cannabis
legislation
State public health funding per person
State cigarette excise tax rate
Year of observation (2014 = 0, 2015 = 1)

PSO
PSH
UR
SUI
PH
ED
BD
C
F
T
YR

Expected
Sign

5.05

Std.
Dev.
3.59

20.530

6.58

+

10.44

6.05

+

0.06
7.04
1359.7
0.0187

0.01 Ambiguous
2.92
+
283.19
+
0.04
+

0.164

0.03

Ambiguous

0.57

0.5

-

40.5
1.78
.5

39.09
1.12
.5

Ambiguous
Ambiguous
Ambiguous

The initial specification of the empirical model is:
(S1)

Y = β0 + β1 PSO + β2 PSH + β3 UR + β4 SUI + β5 PH + β6 ED + β7 BD + β8 C + β9 F +

β10 T + β11 YR + ɛ
45

where Y equals the natural and semi-synthetic opioid overdose deaths excluding heroin per
100,000 persons.

Regression analysis was used to evaluate three model specifications of the model in
Microsoft Excel. The empirical results for all specifications are reported in Table 2. The Rsquared value measures the proportion of the variation in the dependent variable (Y) explained
by the independent variables for a linear regression model. The adjusted R-squared adjusts the
statistic based on the number of independent variables in the model. The adjusted R2 for the
initial model (S1) is 0.6427 which means that 64.27% of the Y is explained by the independent
variables in the specification. One variable, PSH, has a different sign than expected in the initial
regression (S1) results. The F-test for a linear regression indicates whether any of the
independent variables in a multiple linear regression model are jointly significant. The F-test
indicates that the variables are jointly significant at α= 0.001. The t-tests indicate that PSO and F
are significant at α= 0.01, SUI and ED are significant at α= 0.10, while all other variables are
insignificant. Tests for superfluous variables and omitted variables tests suggest that PSH and T
are superfluous, and they were removed from the model.
The second specification is:
(S2)

Y = β0 + β1 PSO + β2 UR + β3 SUI + β4 PH + β5 ED + β6 BD + β7 C + β8 F + β9 YR + ɛ.

The adjusted R2 increased only slightly from 0.6427 in specification (S1) to 0.6581 in
specification (S2). Multicollinearity is when one independent variable in a multiple regression
model can be used to predict another independent variable. Multicollinearity generally occurs
between two or more independent variables that have a high correlation. Their correlation
creates redundant information in the model. Multicollinearity may produce overinflated standard
errors, consequently, independent variables that should be statistically significant are found to be
statistically insignificant.
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A test for multicollinearity indicates no serious collinearity between the independent
variables. The variance inflation factor (VIF) quantifies the severity of multicollinearity in an
ordinary least squares regression analysis and provides an index that measures how much an
estimated regression coefficient is increased because of collinearity. If the VIF value is above 5,
multicollinearity may be problematic for that independent variable. All of the VIF values are all
below 4.
Heteroskedasticity occurs when the variability of the error term varies with the
independent variables. The White test is a general approach which tests for the presence of
heteroskedasticity in the model. The White test indicates that heteroskedasticity is present at the
5% level. The Park test is used to test individual variables for heteroskedasticity. The Park test
for Preventable Hospitalizations (PH) indicates the presence of heteroskedasticity, therefore, PH
was removed from the model.
The third specification of the model is:
(S3)

Y = β0 + β1 PSO + β2 UR + β3 SUI + β4 ED + β5 BD + β6 C + β7 F + β8 YR + ɛ

The adjusted R2 decreased in the third model specification but not significantly. The
final specification (S3) is consistent with theory. Three variables are significant at α= .01
(prescription sales of oxycodone per 100,000 persons, percent of civilians who visited an
emergency department during the past year, and state public health funding per person), one
variable is significant at α= 0.05 (firearm suicides per 100,000 persons), and one variable is
significant at α= 0.10 (presences of legal medical or recreational cannabis legislation), and two
variables (the unemployment rate and percent of adults binge drinking during the past 30 days)
are insignificant.
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Serial correlation is a potential problem for time-series data. Serial correlation is the
correlation of an observation with a delayed copy of itself as a function of delay. The Durbin–
Watson statistic is a test statistic used to detect the presence of first order serial correlation when
errors in one-time period are correlated with errors in the next time period. The Durbin-Watson
test suggests that serial correlation is not present in the final specification (S3). Tests for
multicollinearity indicate no collinearity between the independent variables. However, there is
some heteroskedasticity with the model specification. The heteroskedasticity is likely due to the
limited number of observations and omitted variables reflecting the complexity of the opioid
epidemic.
In summary, the regression analysis based on state-level data is consistent with theory
and prior empirical research. The adjusted R2 is 0.6448; the final specification has an
explanatory power of 64.48%. Empirical results suggest that there is a highly significant positive
association between natural and semi-synthetic opioid overdose deaths and prescription sales of
oxycodone (α= 0.01). These results are similar to prior empirical studies and highlight the
important role that prescriber behavior plays in determining opioid overdose deaths.
The empirical results also suggest the importance of user behavior and characteristics.
Emergency department visits have a highly significant positive association with natural and
semi-synthetic opioid overdose deaths (α= .01). As mentioned earlier, frequent emergency
department visits have been linked to nonmedical opioid use, drug diversion and poorly managed
pain (Brady et al 2015). Firearm suicide rates are also significantly and positively correlated with
opioid overdose deaths (α= .05), suggesting that mental health status is an important determinant
in opioid overdose deaths. This is consistent with research by Davis et al (2017) who find that
having a mental health disorder significantly increases the likelihood or treating pain with
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opioids. Although binge drinking is insignificant, it is negatively associated with opioid overdose
deaths which implies opioids and alcohol may be substitute goods.
The importance of environmental and systemic factors is also supported by the results
based on state level data. The presence of legal cannabis legislation has a significant negative
association with opioid overdose deaths (α= .10). These results suggest that cannabis and
opioids may be substitutes, possibly because both drugs relieve pain. The unemployment rate is
insignificant. This is consistent with some of the prior research that suggests that the weak
relationship that exists between economic decline and drug mortality rates is mostly explained by
confounding factors (Ruhm 2018).
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Independent
Variables
PSO
PSH
UR
SUI
PH
ED
BD
C
F
T
YR
Constant
Adjusted R2

Table 2
State Level Results
Dependent Variable: Y
Coefficients
(P-values)
(S1)
(S2)
0.1993***
0.2041***
(0.0100)
(0.0023)
-0.0141
__
(0.8931)
34.6347
31.7127
(0.4606)
(0.4239)
0.5316*
0.5013***
(0.0850)
(0.0053)
0.0033
0.0031*
(0.1757)
(0.0991)
19.7035*
20.3075*
(0.0956)
(0.0540)
9.1051
8.4535
(0.6468)
(0.6485)
-0.0080
-0.0298
(0.9941)
(0.9750)
0.0410***
0.0405***
(0.0001)
(0.00001)
0.0027
__
(0.9958)
0.0780
0.0786
(0.9061)
(0.9030)
-15.9469*
15.5188**
(0.0268)
(0.0137)
0.6427
0.6581

(S3)
0.2165***
(0.0015)
__
50.2381
(0.1978)
0.2999**
(0.0201)
__
29.0558***
(0.0023)
-0.2936
(0.9871)
-1.1614*
(0.0931)
0.0379***
(0.00003)
__
0.2152
(0.7415)
-10.6586*
(0.0554)
0.6448

***Significant at the 1% level
**Significant at the 5% level
*Significant at the 10% level

B. County Level Analysis
1. Data
The second empirical model uses county level cross-sectional data for the year 2017 to
examine factors related to opioid overdose deaths in the United States. Observations from
counties in Kentucky, Ohio, Pennsylvania, Virginia, and West Virginia are used in this analysis.
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A total of 68 observations were used. All the data for the independent variables in the model
was obtained from the County Health Rankings & Roadmaps database. Data for the dependent
variable, opioid overdose deaths, was obtained from the CDC Wonder database.
2. Model Specification and Regression Results
As in the state level analysis, proxies for prescriber behavior, user behavior and
characteristics, and environmental and systemic factors are used to explain overdose mortality in
model specifications at the county level.
The opioid prescribing rate per 100 persons (OPR) is included as a measure of prescriber
behavior within a county. Opioid prescriptions increase access to opioids and make opioid
addiction more likely. The opioid prescribing rate is expected to be positively associated with
opioid overdose deaths (Paulozzi et al 2011b).
Four variables are used as measures of user behavior and characteristics. The variables
include the average number of physically unhealthy days reported by an individual per month
(PUD), the percent of adults reporting frequent mental distress (FMD), binge drinking behavior
measured as the percent of adults reporting excessive drinking (BD), and preventable hospital
stays, calculated from discharges for ambulatory care sensitive conditions per 1,000 Medicare
enrollees (PHS).
Both the average number of physically unhealthy days reported by an individual per
month and the percent of adults reporting frequent mental distress are expected to be positively
associated with the opioid mortality rate. As the review of the literature suggests, physical and
mental health status are factors that determine the dosage and rate of opioid prescribing. Having
a mental disorder significantly increases the likelihood of treating pain with opioids (Davis et al
2017).
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Binge drinking behavior and preventable hospital stays are included as variables in both
the state and county analysis. As discussed in the state level analysis, the overall relationship
between binge drinking behavior and opioid overdose mortality is ambiguous, and preventable
hospital stays are expected to be positively correlated with opioid overdose deaths.
Five variables are used to measure environmental and systemic factors. The variables
include the unemployment rate (UR), the percent of children in poverty (CP), the high school
graduation rate (HS), the percent of uninsured adults (UI), and the number of primary care
physicians per 100,000 persons (PCP).
The unemployment rate is included as a variable in both the state and county analysis. As
discussed in the state level analysis, the overall relationship between the unemployment rate and
opioid overdose mortality is ambiguous. The percentage of children in poverty is predicted to
be positively associated with opioid overdose deaths as lower-income individuals are more likely
to abuse opioids relative to the general population (Jones 2016). The percent of uninsured adults
has an ambiguous association with opioid overdose deaths. Insurance provides access to
addictive opioid prescriptions but uninsured individuals are associated with poverty which
suggests a greater risk for opioid abuse (Chase 2019, Orgera and Tolbert 2019, Jones 2016).
High school graduation rates are expected to be negatively correlated with opioid overdose
deaths (independent of income) as more educated individuals are produce health more
efficiently. For example, more educated individuals have a greater ability to understand the
negative consequences of unhealthy behaviors (Grossman 1972). The net effect of the number of
primary care physicians per 100,000 persons on opioid overdose mortality is uncertain. Although
an increase in primary care physicians may increase access to health care and the opportunity for
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more effective treatments for addiction, an increase in physicians may also be associated with an
increase in opioid prescriptions to treat pain.
An explanation of the variables and descriptive statistics is in Table 3. Descriptive
statistics are based on data from 68 counties in 2017. The sample includes 68 observations.
Table 3
Label

Variable

Mean

Y

Crude rate of accidental poisoning by and exposure
to narcotics and psychodysleptics [hallucinogens]
Percent of adults reporting frequent mental distress
Percent of adults reporting excessive drinking
Unemployment Rate
Opioid Prescribing Rate per 100 persons
Percent of Children in Poverty
High School Graduation Rate
Primary care physicians per 100,000 persons
Average number of reported physically unhealthy
days per month
Preventable hospital stays; discharges for
ambulatory care sensitive conditions/Medicare
enrollees * 1,000
Percent of adult population uninsured

24.484

Std.
Dev.
15.672

11.537
17.431
5.014
63.791
19.506
84.475
79.589
3.670

1.361
+
2.256 Ambiguous
0.951 Ambiguous
16.692
+
7.866
+
8.292
25.922 Ambiguous
0.546
+

54.142

12.053

+

10.197

2.227

Ambiguous

FMD
BD
UR
OPR
CP
HS
PCP
PUD
PHS
UI

Expected
Sign

The initial specification of the model is:
(C1) Y = β0 + β1 FMD + β2 BD + β3 UR + β4 UR + β5 OPR + β6 CP + β7 HS + β8 PCP + β9 PUD + β10
PHS + β11 UI + ɛ
where Y = the crude rate of accidental poisoning by and exposure to narcotics and
psychodysleptics [hallucinogens].8

Regression analysis was used to evaluate three model specifications of the model in
Microsoft Excel. The empirical results for all specifications are reported in Table 4. The signs

8

I was unable to find strictly opioid overdose deaths for the county data. However, opioids contribute to the
majority of the deaths caused by accidental poisoning by and exposure to narcotics and psychodysleptics
[hallucinogens].
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on all variables in the initial model specification (C1) are consistent with predictions with the
exception of the rate of high school graduates. The F-test indicates that the variables are jointly
significant at α= 0.001. The t-tests indicate that one variable, the unemployment rate (UR), is
significant at α= 0.01. Tests for superfluous variables and omitted variables suggest that FMD is
superfluous, and it was removed from the model.
The second specification is:
(C2)

Y = β0 + β1 BD + β2 UR + β3 UR + β4 OPR + β5 CP + β6 HS + β7 PCP + β8 PUD + β9 PHS

+ β10 UI + ɛ

There is almost no change in the adjusted R2 in the second model specification (0.4515 in
the first specification and 0.4586 in the second specification). Even though the high school
graduation rate is insignificant, the sign remains positive. Multicollinearity tests indicate
potential collinearity problems with two variables, CP and PUD as their VIF values exceeded 5.
When the variable, CP was removed from the model, the VIF values for the all remaining
variables were below 5. The White test indicates that impure heteroskedasticity is present in this
specification of the model. The Weighted Least Squares (WLS) is a method used to remove
heteroscedasticity. WLS incorporates weights associated with each data point. The size of the
weight indicates the precision of the information contained in the associated observation. All of
the variables are rates or percentages and WLS did not yield improved results in the third
specification. The variable, PHS was removed to reduce the heteroscedasticity.
The third specification of the model is:
(C3) Y = β0 + β1 BD + β2 UR + β3 OPR + β4 HS + β5 PCP + β6 PUD + β7 UI + ɛ
Once again, the adjusted R2 did not change significantly. The signs of all variables in the
final specification (C3) is consistent with those that were hypothesized. Two variables are
significant at α= 0.01 (Unemployment Rate, UR and Physically Unhealthy Days, PUD), one
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variable is significant at α= 0.05 (Opioid Prescribing Rate, OPR), and the remaining four
variables (Binge Drinking, BD; High School Graduation, HS; Primary Care Physicians, PCP,
and Uninsured, UI) are insignificant. Serial correlation is often not present in cross-sectional
data, and correlation tests indicated there were no problems with correlation. The White test
indicates that impure heteroskedasticity is present in this specification of the model; however, the
heteroskedasticity was less of problem for the final specification (C3) than the previous
specification (C2). All of the variables are rates or percentages, so it is not surprising that WLS
did not yield improved results in the third specification (C3). The impure heteroskedasticity is
likely due to the limited number of observations and omitted variables reflecting the complexity
of the opioid epidemic.
In summary, the regression analysis based on county level data is consistent with theory
and prior empirical research. The adjusted R2 is 0.4448; the final model has an explanatory
power of 44.48%. The results suggest that opioid prescription rates have a significant and
positive correlation with opioid overdose deaths (α= 0.05). This result is consistent with the
analysis at the state level and with prior empirical studies. It provides additional evidence that
prescriber behavior plays an important role in determining opioid overdose deaths.
The empirical results also suggest the importance of user behavior and characteristics.
There is a strong significant positive association between opioid overdose deaths and physically
unhealthy days (α= 0.01). Individuals who are physically unhealthy are more likely to suffer
from chronic pain or high impact chronic pain and to be treated with opioids. The impact of
chronic pain is associated with restrictions in daily activities while high impact chronic pain is
debilitating, leading to major limitations in work, social, recreational, and self-care activities
(CDC 2018). Theoretically, the relationship between binge drinking and opioid deaths is
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ambiguous, depending on whether alcohol and opioids are substitutes or complements. In both
the state and county analysis, binge or excessive drinking is negatively correlated with opioid
overdose deaths. Even though the relationship is insignificant, this may imply that alcohol and
opioids are weak substitutes.
The importance of environmental and systemic factors is also supported by the results
based on county level data. The empirical results at the county level suggest a highly significant
negative association between opioid overdose deaths and the unemployment rate (α= 0.01).
Although this result differs from the insignificant positive association with unemployment found
in the analysis based on state level data, the empirical literature on the relationship of
unemployment and opioid abuse is mixed. Harris et al (2019) find a significant negative effect
between opioid prescriptions and the unemployment rate. Other empirical studies imply a weak
relationship between economic decline and drug mortality rates which is mostly explained by
confounding factors (Ruhm 2018). Finally, Currie et al (2018a) suggest that no simple causal
relationship exists between economics conditions and opioid abuse. The final variable used to
measure environmental and systemic factors, high school graduation rates, has an insignificant
negative association with opioid overdose morality. These results, while insignificant, imply
education and an increase in economic opportunity is a deterrent to opioid overdose deaths.
Primary care physician per 100,000 persons and the uninsured population were also
included in the regression model to capture environmental and systemic factors. Both variables
have insignificant negative associations with opioid overdose morality. In theory, greater access
to medical care either because there are more physicians available to treat patients or because
there are more insured individuals who can afford care, has an ambiguous relationship to opioid
mortality. Prescriber behavior varies widely among physicians and as the number of physicians
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and the number of insured patients increase, this may provide greater access to opioid
prescriptions. On the other hand, an increase in physicians and insured individuals may provide
access to better and more effective pain management leading to fewer opioid prescriptions.
These results suggest that more physicians are associated with fewer prescriptions. New
guidelines for prescribing practices and managing pain have been implemented in recent years
leading to a decline in opioid prescribing rates. The county level results also suggest that an
increase in the rate of uninsured individuals leads to a decrease in opioid overdose deaths which
may suggest that greater access to medical care leads to more opioid prescriptions for pain.
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Independent
Variables
FMD
BD
UR
OPR
CP
HS
PCP
PUD
PHS
UI
Constant
Adjusted R2

Table 4
County Level Results
Dependent Variable: Y
Coefficients
(P-values)
(C1)
(C2)
2.3615
__
(0.7989)
2.3615
-1.7659*
(0.6209)
(.0886)
-9.4963***
-9.6217***
(0.0011)
(0.0008)
0.1855
0.1800
(0.1551)
(0.1631)
0.6733
0.8263
(0.2735)
(0.1189)
0.1656
0.1471
(0.4900)
(0.5318)
-0.0140
-0.0134
(0.8236)
(0.8297)
7.5456
12.0032
(0.5011)
(0.5014)
0.1063
0.0852
(0.6478)
(0.7074)
-1.1012
-1.3321
(0.3710)
(0.2400)
13.8110
29.4623
(0.7989)
(0.5014)
0.4515
0.4586

***Significant at the 1% level
**Significant at the 5% level
*Significant at the 10% level
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(C3)
__
-1.0264
(0.2680)
-7.3811***
(0.0027)
0.2429*
(0.0523)
__
-0.0300
(0.8857)
-0.0024
(0.9698)
17.9789***
(0.0017)
__
-0.2866
(0.7562)
1.8438
(0.9628)
0.4448

V.

Conclusions
Over the last two decades, the opioid epidemic has led to serious negative consequences.

Opioid addiction adversely affects an individual’s mental and physical health. In addition, the
societal and economic costs are substantial. Opioid addiction is associated with an increase in
other diseases such as hepatitis, domestic and child abuse, crime, lost wages and employment.
Although the causes of the opioid crisis were multifaceted, primary factors were an increased
demand for pain treatment, two widely cited notes based on observations of patients suffering
from acute and chronic pain which underestimated opioid addiction risk, the recognition of pain
as a vital sign, and aggressive pharmaceutical marketing for opioid prescriptions.
This study investigates the risk factors that are associated with opioid addiction. The
opioid overdose mortality rate is used as a measure of the seriousness of the opioid epidemic.
Theoretical concepts from Grossman’s production function of heath (1972) and Becker and
Murphy’s model of rational addiction (1988) are used to develop empirical models that explore
the relationship between risk factors and opioid overdose deaths.
The production function of health summarizes the relationship between health inputs
such as medical care and lifestyle and health outcomes such as life expectancy. Medical services
and the time devoted to the production of health impact an individual’s health. Depreciation in
health is related to age and behavioral factors such as alcohol consumption, smoking, and
obesity. Addiction to substances such as opioids also leads to a deterioration in health stock.
Becker and Murphy developed a model in which individuals rationally choose to consume
addictive goods. Their model implies that addiction is more likely in individuals who discount
the future heavily, that is, these individuals focus less on the future effects from current
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consumption choices. Their model also implies that individuals respond to price increases in
specific addictive substances by consuming cheaper substitute goods.
More broadly, Grossman’s model of health suggests that health outcomes are affected by
a variety of health factors which include clinical care, health behaviors, social and economic
factors, and environmental characteristics. Clinical care includes both access to care and quality
of care. Health behaviors include decisions about diet, exercise, and use of cigarettes, alcohol,
and drugs. Social and economic factors include employment, income, education, family, social
support, and community safety. Characteristics of the physical environmental include housing
and transit. Following King et al (2014), health factors that affect the opioid mortality rate are
grouped into three broad categories: prescriber behavior, user behavior and characteristics, and
environmental and systemic factors.
The empirical analysis examines the relationship between risk factors that are associated
with prescriber behavior, user behavior and characteristics, environmental and systemic factors
and opioid overdose mortality. Two regression models are used to analyze data at the state and
county level. The state level analysis is based on panel data. The county level analysis is based
on cross-sectional data.
The behavior of prescribers may increase the risk associated with opioid overdose deaths
in several ways and it has been shown to play a key role in opioid-related overdose deaths. Three
measures of prescriber behavior are initially included in this study: prescriptions sales of
oxycodone and hydrocodone at the state level and opioid prescribing rates at the county level.
Prescription sales of hydrocodone was dropped from the empirical model after tests indicated
that it was superfluous. Both analyses at the state and the county level indicate that there is a
significant positive association between prescriber behavior and opioid overdose mortality. The
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empirical results at the state level indicate that an increase in the prescription sales of oxycodone
are statistically associated with an increase in natural and semi-synthetic opioid overdose deaths
at the 1% level. Similarly, the analysis at the county level suggests that an increase in opioid
prescription rates is positively correlated with the crude rate of accidental poisoning by narcotics
and psychodysleptics at the 5% level. While the latter measure of opioid overdose mortality
includes substances that are not opioids, opioids make up the majority of those substances. These
results highlight the important role that prescriber behavior plays in determining opioid overdose
deaths and in contributing to the opioid epidemic. The results are consistent with many empirical
studies described in the literature review and are also consistent with the historical events
described in the introduction, where aggressive pharmaceutical marketing of opioids is linked to
the opioid epidemic.
The behavior of users and user characteristics may also increase the risk associated with
opioid overdose deaths. Variables used to measure user behavior and characteristics in the state
level analysis include preventable hospitalizations, emergency department visits, binge drinking,
and firearm suicides. Variables used to measure user behavior and characteristics in the county
level analysis include preventable hospitalizations, binge drinking, frequent mental distress, and
physically unhealthy days.
Both the empirical analysis at the state and county level result in a final specification in
which preventable hospital stays are removed due to the presence of heteroskedasticity.
However, emergency room visits are statistically associated with opioid overdose mortality at the
1% level in the state level analysis. This is consistent with prior studies which find a strong
association between the rate of emergency department visits and an increased risk for overdoses
from prescription drugs (Brady et al 2015).
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Although binge drinking behavior is included in both empirical models, it is insignificant.
Theoretically, the overall relationship between binge drinking and opioid overdose mortality is
ambiguous, and depends on whether alcohol and opioids are substitutes or complements. While
not significant in either model, an increase in binge drinking suggests a decline in the opioid
overdose mortality rate which implies that alcohol and opioids may be substitutes. However, the
empirical results are mixed and some researchers find evidence of a complementary relationship
(Esser et al (2019).
As with preventable hospitalizations, firearm suicides are associated with mental
disorders, chronic pain, and substance abuse (Meiman et al 2015; Ilgen et al 2016; Martin 2018).
Consistent with these findings, firearm suicide rates are positively correlated with opioid
overdose deaths at a 5% level of significance in the state level analysis. Both physical and mental
health status are factors that determine the dosage and rate of opioid prescribing. The presence of
a mental disorder significantly increases the likelihood of treating pain with opioids (Davis et al
2017). The county level analysis suggests that an increase in physically unhealthy days is
associated with an increase in opioid overdose mortality at the 1% significance level. Although
frequent mental distress was initially included in the county level analysis, it was removed from
the final specification because tests suggested that it was a superfluous variable.
The final broad category of health factors that affect the opioid mortality are
environmental and systemic factors. Variables used to measure environmental and systemic
factors in the state level analysis include the unemployment rate, per capita state public health
funding, the state excise tax on cigarettes, and the existence of medical or recreational cannabis
legislation. Variables used to measure environmental and systemic factors in the county level
analysis include the unemployment rate, the percent of children in poverty, the high school
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graduation rate, the percent of uninsured adults, and the number of primary care physicians per
100,000 persons.
The unemployment rate is included in both the state and county analysis. The effect of
the unemployment rate on opioid overdose deaths is ambiguous. Theoretically, as the
unemployment rate increases and economic conditions decline, an increase in opioid abuse and
overdoses would be expected. However, evidence on the relationship between the unemployment
rate and the opioid overdose rate is mixed. In addition, some studies find evidence of reverse
causality between these two variables, that is, opioid abuse has a negative impact on the
unemployment rate (Harris 2019). Although the unemployment rate is positively associated with
opioid overdose mortality in the state analysis, it is insignificant. The empirical results at the
county level suggest that the unemployment rate is negatively correlated with opioid overdose
deaths and is statistically significant at the 1% level.
The net effect of state public health funding per person on opioid overdose deaths is
ambiguous. While state public health public funding can be used to increase measures to combat
the opioid epidemic, public health funding also increases access to health care and pain
prescriptions such as opioids. Public per capita health funding is positively related to opioid
overdose deaths and significant at the 1% level in the state level analysis. This suggests that an
increase in public health funds may have an overall effect of increasing access to opioids.
Cigarettes and cannabis are alternative addictive goods. In theory, the impact of the state
excise tax on cigarettes on the opioid overdose death rate is ambiguous, depending on whether
cigarettes serve as a substitute or a complement to opioid use. Cigarette excise taxes were
included in the state level analysis, however, this variable was removed from the model after test
indicated that it was superfluous. Opioid overdose deaths have been driven by prescriptions to
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treat chronic pain. Because medical cannabis is used to treat pain, states in which medical
cannabis is legal may have lower rates of opioid abuse and overdose deaths. The presence of
cannabis legislation is significant at the 10% level and is negatively associated with opioid
overdose deaths in the state level analysis. These results suggest that cannabis and opioids are
substitutes, which is consistent with the empirical findings in Bachhuber et al (2014) and
(Chihun and Li et al (2019).
The final environmental and systemic risk factors are measures at the county level. These
measures include the percent of children in poverty, the high school graduation rate, the percent
of uninsured adults, and the number of primary care physicians per 100,000 persons. The
percentage of children in poverty was removed from the model after tests indicated significant
multicollinearity. The percent of uninsured adults has an ambiguous association with opioid
overdose deaths. Insurance provides access to addictive opioid prescriptions but uninsured
individuals are associated with poverty which suggests a greater risk for opioid abuse (Chase
2019, Orgera and Tolbert 2019, Jones 2016). Although the uninsurance rate is insignificant, it is
negatively associated with opioid overdose mortality, suggesting that more access to medical
care provides more access to opioid prescriptions. High school graduation rates are expected to
be negatively correlated with opioid overdose deaths (independent of income) as more educated
individuals are produce health more efficiently. For example, more educated individuals have a
greater ability to understand the negative consequences of unhealthy behaviors (Grossman 1972).
High school graduation rates have an insignificant negative association with opioid overdose
morality. Although these results, are insignificant, the negative association implies that
education and an increase in economic opportunity is a deterrent to opioid overdose deaths.
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The net effect of the number of primary care physicians per 100,000 persons on opioid
overdose mortality is uncertain. Although an increase in primary care physicians may increase
access to health care and the opportunity for more effective treatments for addiction, an increase
in physicians may also be associated with an increase in opioid prescriptions to treat pain. The
statistical relationship between primary care physicians and the opioid overdose mortality rate is
insignificant but negative, which suggests that more physicians are associated with fewer
prescriptions. This result may be due, in part, to prescribing guidelines. New guidelines for
prescribing practices and managing pain have been implemented in recent years leading to a
decline in opioid prescribing rates.
A major theme of this paper is that understanding the opioid epidemic is complex. The
empirical results at the state and county level suggest that there are many risk factors associated
with opioid overdose mortality. Additionally, the opioid crisis has not impacted the nation in a
uniform way. In particular, some communities, such as counties in Kentucky, Ohio, West
Virginia, and Pennsylvania have been impacted much more severely than others. Finally, the
opioid drug problem has evolved in different ways over time for specific communities. Some
counties and states now have severe problems with heroin and fentanyl. As many empirical
researchers have suggested, more studies at the community level are needed as many factors
contribute to the institutional environment faced by different regions of the country. The
complexity of the opioid epidemic is consistent with Grossman’s model of health in which health
outcomes are affected by a variety of health factors which include clinical care, health behaviors,
social and economic factors, and environmental characteristics.
An implication of this analysis and similar empirical studies is that addressing the opioid
epidemic requires multifaceted and targeted solutions in order to effectively and efficiently
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allocate resources. Additionally, developing effective policy solutions in addition to treatment
options for opioid addiction requires an interdisciplinary approach. As discussed earlier, the
range of relevant knowledge includes the biological/chemical and non-biological causes of
addiction, pain prevalence and its management, the historical events leading to the role of
opioids in treating pain, and knowledge about the epidemic from empirical studies based on
analyses at several levels including individuals, communities, and states. The results of
empirical studies focused on the opioid epidemic can guide legislators as they propose policies to
reduce and treat opioid addiction or addiction to other substances.
In particular, this study suggests that opioid prescriptions (prescriber behavior), mental
and physical health and emergency department visits (user behavior and characteristics), and
cannabis legislation (environmental and systemic factors) are all important risk factors in opioid
overdose deaths. These findings have several implications. First, solutions to combat the opioid
epidemic will involve balancing the need to effectively manage chronic pain while preventing
opioid addiction and abuse. Second, effective solutions will involve multiple strategies which
restrict the supply and reduce the demand for opioids. The strong association between opioid
prescriptions and opioid overdose mortality implies that strategies to restrict the legal access of
opioids, such as preventing drug diversion, prescription drug monitoring programs, provider
education, and prescribing guidelines might be effective. Strategies to reduce the demand for
opioids may include educating patients about the dangers of opioid use. In addition, increasing
access to treatment for addiction disorders and access to medical care for individuals with mental
and physical impairment may reduce opioid use. Finally, reducing the harmful consequences
associated with opioid addiction by increasing the availability of naloxone to reverse overdoses
or increasing buprenorphine to reduce withdrawal symptoms would be helpful. Policies that
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regulate substances that serve as opioid substitutes may also be useful in reducing opioid abuse.
The results from the state level analysis suggest that policies that legalize cannabis may be
helpful in reducing opioid overdose deaths. Overall, the results of this paper support the need for
the development of public health policies which are designed on the basis of empirical
information. Targeting strategies to specific local needs can more effectively improve both the
health of individuals and the economic and societal well-being of communities.
In conclusion, this study suggests the need for future research. While my empirical
results were consistent with much of the previous literature, there are ways in which my study
could be improved and expanded. As more data becomes available, incorporating additional
variables, observations, and modeling techniques could improve the ability of the model to
predict opioid overdose deaths. For example, I initially planned to examine the impact of state
laws passed to limit prescription opioids (PDMPs) on opioid overdose mortality. As discussed in
the review of the literature, some research suggests that PDMPS are not significant in reducing
opioid overdose deaths. However, state laws regarding drug monitoring programs differ. Some
state laws simply make information on prior opioid prescriptions received by patients available
to physicians while other states require physicians to look at prior opioid prescriptions received
by their patients. Programs that require physicians to examine prior opioid prescriptions given to
their patients are significantly related to a reduction in opioid overdose deaths. As I collected
data on PDMPS, I realized that including this variable would require access to a more detailed
dataset. Although all states except one have passed drug monitoring programs, the laws vary not
only by whether the physician is required to look at the patient history of drug prescriptions, but
also by the specific type of prescription monitored and by the type of physician specialist
required to access the patient history. I had also planned to examine the impact of a county
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legislation on alcohol sales explore whether a county was dry or wet had an impact on opioid
overdose mortality. However, almost all of the counties in the data set where wet. Furthermore,
the ability to access and use data at the individual level would be helpful in examining the impact
of demographic characteristics on the risk for opioid overdose deaths. Finally, using a more
complicated time-series cross-sectional modeling approach could improve both the state and
county level analysis.
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